Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AM 3301

Drug Profile

AM 3301

Alternative Names: AM3301; ME 3301

Latest Information Update: 31 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Amalyte Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Small molecules
  • Mechanism of Action Cytokine inhibitors; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Hypersensitivity; Ulcerative colitis

Most Recent Events

  • 01 Apr 2011 Meiji Seika Kaisha is now called Meiji Seika Pharma
  • 25 Feb 2011 Phase-II development is ongoing
  • 11 Jun 2009 AM 3301 licensed to Amalyte Pharmaceuticals worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top